Pfizer's Announced The Launch Of Trastuzumab Biosimilar For Global Herceptin Biosimilar Market
The growing prevalence of cancers such as breast cancer in women is driving the growth of the global Herceptin biosimilar market. According to the World Health Organization’s report published in 2019, approximately 627,000 women across the globe died from breast cancer and it accounted for around 15% of all cancer deaths among women in 2018. Also, the rising prevalence of gastric cancers such as metastatic gastric cancer is again contributing to the growth of the Herceptin biosimilar market. According to the US National Library of Medicine’s report published in 2018, gastric cancer is the fifth most common neoplasm in people and the third most deadly cancer across the globe. According to the same source, gastric cancer accounted for around 783,000 death globally in 2018. Key players engaged in the global Herceptin biosimilar market include AryoGen Biopharma, Amgen Inc., Biocon Limited, Pfizer Inc., Merck & Co., Inc., Celltrion Inc., Accord Healthcare Ltd, Gedeo...